Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

Apr

Components of Antibody Drug Conjugates

Introduction to Antibody Drug ConjugatesMalignant tumors have become the second largest health threat worldwide. However, most chemotherapy drugs have a low therapeutic index and commonly cause seriou...

Read article >

Apr

The Mechanism of Action of Bispecific Antibody Therapy

Introduction to Bispecific Antibody TherapySo far, compared with traditional cancer treatment strategies, immunotherapy is considered the most promising systemic tumor treatment method. Among them, mo...

Read article >

Mar

The Role and Development Trends of Antibody Drugs

The Role of Antibody DrugsThe greatest challenge in cancer treatment is to eradicate cancer cells while minimizing the loss of normal cells. To address this challenge, targeted therapies have been dev...

Read article >